Watch BIAFW. Know when insiders buy.
One email the day a filing lands. Free.
BIAFW
bioAffinity Technologies, Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM $5.9M −23.2%NET INCOME −$15.2MNET CASH —52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.5M | +19.0% | — | −$3.3M | −$3.4M | — | -0.64 | −$3.2M | $90K | −$3.3M | Aug 7 |
| Q1 2026 · Mar 31 | $1.4M | −27.1% | — | −$3.6M | −$3.6M | — | -0.81 | −$3.2M | $6K | −$3.2M | May 11 |
| Q4 2025 · Dec 31derived | $1.6M | −27.8% | — | −$3.1M | −$3.1M | — | -1.11 | −$2.6M | $1 | −$2.6M | Mar 16 |
| Q3 2025 · Sep 30 | $1.4M | −38.5% | — | −$2.3M | −$5.1M | — | -4.74 | −$2.5M | −$4K | −$2.5M | Nov 14 |
| Q2 2025 · Jun 30 | $1.3M | −47.1% | — | −$2.5M | −$4.1M | — | -5.07 | −$2.6M | $13K | −$2.7M | Aug 7 |
| Q1 2025 · Mar 31 | $1.9M | −23.0% | — | −$2.6M | −$2.7M | — | -4.80 | −$1.6M | $51K | −$1.7M | May 11 |
| Q4 2024 · Dec 31derived | $2.2M | −2.4% | — | −$2.9M | −$3M | — | -6.28 | −$1.7M | $1 | −$1.7M | Mar 16 |
| Q3 2024 · Sep 30 | $2.4M | +682.8% | — | −$2M | −$2M | — | -4.84 | −$1.7M | $9K | −$1.7M | Nov 14 |
| Q2 2024 · Jun 30 | $2.4M | — | — | −$2.1M | −$2.1M | — | -0.19 | −$1.5M | $28K | −$1.6M | Aug 14 |
| Q1 2024 · Mar 31 | $2.4M | — | — | −$1.9M | −$2M | — | -0.20 | −$2.3M | $41K | −$2.4M | May 15 |
| Q4 2023 · Dec 31derived | $2.3M | — | — | −$2.3M | −$2.4M | — | -0.26 | −$1.6M | −$13K | −$1.6M | Mar 31 |
| Q3 2023 · Sep 30 | $300K | — | 74.5% | −$2.3M | −$2.3M | — | -0.26 | −$1.5M | $169 | −$1.5M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $6.2M | — | −$10.6M | −$14.9M | -242.0% | -8.66 | −$9.3M | $61K | −$9.4M | — | — |
| FY2024 · to Dec 31 | $9.4M | — | −$9M | −$9M | -96.6% | -22.50 | −$7.3M | $79K | −$7.3M | — | — |
| FY2023 · to Dec 31 | $7.9M | — | −$8M | −$7.9M | -100.5% | -0.91 | −$6M | $23K | −$6.1M | — | — |
| FY2022 · to Dec 31 | $6.9M | 0.1% | −$4M | −$8.2M | -118.2% | -1.81 | −$4.1M | $220K | −$4.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$2.2M | −$6.3M | — | -2.36 | −$2M | — | — | — | — |
Every number comes from bioAffinity Technologies, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.